Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?

Table 2

Summary of the gene fusions detected in patients treated with cetuximab and chemotherapy and selected for the extremities of response (see [10]).

Patients harboring gene fusions	N (%)		value^§
	Long PFS (14)	Short PFS (26)
Absence	4/14	12/26	0.3295^§
Presence	10/14	14/26
1 for each patient	5/10	10/14	0.4028^§
>1 for each patient	5/10	4/14
Only mRNA in the fusion	6/10	13/14	0.1222^§
LncRNA in the fusion	8/10	2/14	0.0027^§
CD274/PDCD1LG2 fusion	0/10	7/14	0.0188^§

^§The values are reported as the two-sided Fisher exact test.